W.H. Cornerstone Investments Inc. Acquires 104 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

W.H. Cornerstone Investments Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,294 shares of the medical research company’s stock after buying an additional 104 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.0% of W.H. Cornerstone Investments Inc.’s investment portfolio, making the stock its 22nd biggest holding. W.H. Cornerstone Investments Inc.’s holdings in Thermo Fisher Scientific were worth $1,419,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of TMO. Sentry Investment Management LLC increased its position in shares of Thermo Fisher Scientific by 7.5% during the third quarter. Sentry Investment Management LLC now owns 2,641 shares of the medical research company’s stock worth $1,634,000 after purchasing an additional 185 shares in the last quarter. United Advisor Group LLC raised its stake in Thermo Fisher Scientific by 55.4% in the third quarter. United Advisor Group LLC now owns 701 shares of the medical research company’s stock valued at $434,000 after buying an additional 250 shares during the last quarter. ASB Consultores LLC boosted its holdings in Thermo Fisher Scientific by 34.5% in the third quarter. ASB Consultores LLC now owns 1,056 shares of the medical research company’s stock worth $653,000 after acquiring an additional 271 shares in the last quarter. Martin Investment Management LLC grew its stake in shares of Thermo Fisher Scientific by 1.1% during the third quarter. Martin Investment Management LLC now owns 17,038 shares of the medical research company’s stock worth $10,539,000 after acquiring an additional 190 shares during the last quarter. Finally, Cary Street Partners Asset Management LLC raised its position in shares of Thermo Fisher Scientific by 6.5% in the 3rd quarter. Cary Street Partners Asset Management LLC now owns 5,684 shares of the medical research company’s stock valued at $3,516,000 after purchasing an additional 346 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company’s stock, valued at approximately $7,134,197.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now directly owns 121,192 shares in the company, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,150 shares of company stock worth $10,094,925. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Morgan Stanley upped their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Redburn Atlantic initiated coverage on Thermo Fisher Scientific in a research report on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Bank of America increased their price objective on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, Royal Bank of Canada dropped their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of NYSE TMO opened at $555.47 on Tuesday. Thermo Fisher Scientific Inc. has a 52-week low of $437.26 and a 52-week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company’s 50-day simple moving average is $598.39 and its 200-day simple moving average is $583.86. The firm has a market cap of $212.19 billion, a price-to-earnings ratio of 34.83, a price-to-earnings-growth ratio of 3.69 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business earned $5.69 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.